ReviewCureus2026
Importance of Preconception Reproductive Genetic Screening in Routine Clinical Care.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Advanced maternal age and assisted reproductive technologies: outcomes, genomics, and real-world evidence.Frontiers in reproductive health · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preconception reproductive genetic screening (PRGS) is an increasingly important strategy in preventive reproductive healthcare, enabling the identification of carrier status for autosomal recessive and X-linked disorders in asymptomatic individuals prior to conception. Advances in genomic technologies and expanding professional guidelines have shifted screening paradigms from ethnicity-based approaches toward population-neutral expanded carrier screening, underscoring the need for updated clinical and policy perspectives. The objective of this narrative review is to synthesize contemporary evidence on the clinical utility, technological evolution, ethical considerations, and implementation challenges of PRGS in routine care. A comprehensive literature search was conducted across PubMed, Scopus, Cochrane Library, and Web of Science, covering publications from January 2000 to September 2025. Following removal of duplicates and screening of titles, abstracts, and full texts, 80 studies were included in the final narrative synthesis. The reviewed evidence demonstrated that expanded carrier screening using next-generation sequencing improved detection of at-risk couples compared with traditional targeted approaches and supported informed reproductive decision-making. Integration of PRGS with genetic counseling, assisted reproductive technologies, and emerging digital tools such as artificial intelligence-assisted variant interpretation may further enhance scalability and precision. However, significant barriers persist, including variable insurance coverage, limited access to genetic counseling, underrepresentation of diverse populations in genomic databases, and unresolved ethical and psychosocial concerns. Overall, PRGS represents a clinically valuable and ethically complex preventive strategy with significant public health implications. When responsibly implemented with appropriate counseling, equitable access, and robust policy support, PRGS has the potential to reduce the burden of inherited genetic disorders and advance personalized, patient-centered reproductive care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.